Rigel Pharmaceuticals RIGL Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's change in lease liabilities?
- Rigel Pharmaceuticals (RIGL) reported change in lease liabilities of -$145K in Q1 2026.
- How has Rigel Pharmaceuticals's change in lease liabilities changed year-over-year?
- Rigel Pharmaceuticals's change in lease liabilities decreased by 114.0% year-over-year, from $1.04M to -$145K.
- What is the long-term trend for Rigel Pharmaceuticals's change in lease liabilities?
- Over 3 years (2021 to 2024), Rigel Pharmaceuticals's change in lease liabilities has grown at a -56.9% compound annual growth rate (CAGR), from -$8.62M to -$692K.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.